Holen Sie sich die Stockscreener-App
7.27
6.60%
0.45
Handel nachbörslich:
7.39
0.12
+1.65%
Schlusskurs vom Vortag:
$6.82
Offen:
$6.96
24-Stunden-Volumen:
1.43M
Relative Volume:
1.36
Marktkapitalisierung:
$549.92M
Einnahmen:
$83.57M
Nettoeinkommen (Verlust:
$-4.94M
KGV:
-80.78
EPS:
-0.09
Netto-Cashflow:
$6.97M
1W Leistung:
+3.71%
1M Leistung:
+107.71%
6M Leistung:
+120.30%
1J Leistung:
+408.39%
1-Tages-Spanne:
$6.85
$7.3858
1-Wochen-Bereich:
$6.80
$7.58
52-Wochen-Spanne:
$1.32
$7.58
Chromadex Corp Stock (CDXC) Company Profile
Firmenname
Chromadex Corp
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie CDXC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CDXC | 7.27 | 549.92M | 83.57M | -4.94M | 6.97M | -0.09 |
| KHC | 31.07 | 38.01B | 26.13B | 1.37B | 3.00B | 2.42 |
| GIS | 62.88 | 34.91B | 19.80B | 2.40B | 2.78B | 4.10 |
| K | 80.60 | 27.75B | 12.80B | 1.01B | 927.00M | 2.50 |
| MKC | 74.62 | 19.89B | 6.68B | 792.60M | 774.40M | 2.40 |
| HRL | 29.40 | 16.12B | 11.98B | 780.78M | 902.87M | 1.61 |
Chromadex Corp Stock (CDXC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Chromadex Corp Aktie (CDXC) Neueste Nachrichten
ChromaDex Co. (NASDAQ:CDXC) Short Interest Update - MarketBeat
ChromaDex Expands Niagen IV Access to 200+ Restore Hyper Wellness Clinics - Athletech News
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement - Yahoo Finance
ChromaDex (NASDAQ:CDXC) Sets New 12-Month HighHere's Why - MarketBeat
ChromaDex stock soars to 52-week high, hits $7.08 - Investing.com
ChromaDex (NASDAQ:CDXC) Cut to "Buy" at StockNews.com - MarketBeat
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? - Yahoo Finance
ChromaDex rolls out Niagen IV at wellness centers By Investing.com - Investing.com Australia
What is Roth Capital's Estimate for ChromaDex Q2 Earnings? - MarketBeat
ChromaDex rolls out Niagen IV at wellness centers - Investing.com India
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Research Analysts Issue Forecasts for ChromaDex Q4 Earnings - MarketBeat
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality - Yahoo Finance
ChromaDex (NASDAQ:CDXC) Hits New 12-Month High After Analyst Upgrade - Defense World
ChromaDex's Niagen IV Launches Nationwide: Clinical Data Shows 75% Faster NAD+ Therapy | CDXC Stock News - StockTitan
HC Wainwright Issues Positive Outlook for ChromaDex Earnings - MarketBeat
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
HC Wainwright Brokers Boost Earnings Estimates for ChromaDex - MarketBeat
ChromaDex records 31% sales growth; stock PT raised to $8 by H.C. Wainwright - Investing.com
Are Investors Keen On Selling Holdings In Chromadex Corp (NASDAQ: CDXC)? - Stocks Register
ChromaDex (NASDAQ:CDXC) Given New $8.00 Price Target at HC Wainwright - MarketBeat
BSW Wealth Partners Acquires Shares of 88,847 ChromaDex Co. (NASDAQ:CDXC) - MarketBeat
Roth Capital Estimates ChromaDex's Q2 Earnings (NASDAQ:CDXC) - MarketBeat
ChromaDex (NASDAQ:CDXC) Releases Quarterly Earnings Results - MarketBeat
ChromaDex Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record R - GuruFocus.com
ChromaDex stock soars to 52-week high, hits $4.69 By Investing.com - Investing.com Nigeria
ChromaDex stock soars to 52-week high, hits $4.69 - Investing.com India
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates - MSN
ChromaDex Corp (CDXC) Q3 2024 Earnings: EPS of $0.02 Beats Estimates, Revenue Hits $25.6 Million - GuruFocus.com
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
ChromaDex surges on surprise Q3 profit - XM
ChromaDex: Q3 Earnings Snapshot - New Haven Register
ChromaDex Reports Strong Q3 2024 Financial Results - TipRanks
ChromaDex Corporation Reports Third Quarter 2024 Financial Results - BioSpace
ChromaDex Shares Climb on Forecast for 15% Revenue Growth - MarketWatch
Chromadex Reports Strong Q3 2024 with 31% Sales Increase - TipRanks
ChromaDex reports Q3 EPS 2c, consensus 0c - TipRanks
ChromaDex sees FY24 revenue growth 15% - TipRanks
ChromaDex Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
Curious About NAD+? Here’s How It Works and How to Try It At Home - NewBeauty Magazine
ChromaDex Q3 2024 Earnings Preview - MSN
ChromaDex Corp (CDXC) Q3 2024 Earnings Report Preview: What To E - GuruFocus.com
Insights into ChromaDex's Upcoming Earnings - Benzinga
ChromaDex Co. (NASDAQ:CDXC) Sees Significant Drop in Short Interest - MarketBeat
$9M Fee Awarded For 'Feeble' Milk Vitamin Eligibility Row - Law360
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 - StockTitan
ChromaDex (CDXC) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Finanzdaten der Chromadex Corp-Aktie (CDXC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.79%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):